Zentalis Pharmaceuticals (ZNTL) Competitors

$4.06 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.00 -0.06 (-1.38%)

As of 05/22/2026 06:56 PM Eastern

ZNTL vs. JBIO, AVLN, COLL, XERS, and MRVI

Should you buy Zentalis Pharmaceuticals stock or one of its competitors? MarketBeat compares Zentalis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zentalis Pharmaceuticals include Jade Biosciences (JBIO), Avalyn Pharma (AVLN), Collegium Pharmaceutical (COLL), Xeris Biopharma (XERS), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Zentalis Pharmaceuticals compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Jade Biosciences' return on equity of -51.34% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 1 mentions for Jade Biosciences. Zentalis Pharmaceuticals' average media sentiment score of 0.49 beat Jade Biosciences' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jade Biosciences has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Jade Biosciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Zentalis Pharmaceuticals	$67.43M	4.29	-$137.06M	-$1.73	N/A

Jade Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Jade Biosciences currently has a consensus price target of $34.33, suggesting a potential upside of 54.59%. Zentalis Pharmaceuticals has a consensus price target of $5.83, suggesting a potential upside of 43.68%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Jade Biosciences is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Jade Biosciences and Zentalis Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Avalyn Pharma?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Zentalis Pharmaceuticals currently has a consensus target price of $5.83, indicating a potential upside of 43.68%. Avalyn Pharma has a consensus target price of $66.00, indicating a potential upside of 128.85%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Avalyn Pharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Avalyn Pharma's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Avalyn Pharma	N/A	N/A	N/A

In the previous week, Avalyn Pharma had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 4 mentions for Avalyn Pharma and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.49 beat Avalyn Pharma's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma has lower revenue, but higher earnings than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.29	-$137.06M	-$1.73	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

Summary

Avalyn Pharma beats Zentalis Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Collegium Pharmaceutical has a net margin of 9.41% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.65 beat Zentalis Pharmaceuticals' score of 0.49 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.70
Zentalis Pharmaceuticals	$67.43M	4.29	-$137.06M	-$1.73	N/A

Collegium Pharmaceutical currently has a consensus price target of $57.50, indicating a potential upside of 68.77%. Zentalis Pharmaceuticals has a consensus price target of $5.83, indicating a potential upside of 43.68%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Summary

Collegium Pharmaceutical beats Zentalis Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Xeris Biopharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

42.8% of Xeris Biopharma shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xeris Biopharma has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.66	$550K	$0.06	103.17
Zentalis Pharmaceuticals	$67.43M	4.29	-$137.06M	-$1.73	N/A

Xeris Biopharma presently has a consensus target price of $10.80, suggesting a potential upside of 74.47%. Zentalis Pharmaceuticals has a consensus target price of $5.83, suggesting a potential upside of 43.68%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Xeris Biopharma has a net margin of 3.81% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.84 beat Zentalis Pharmaceuticals' score of 0.49 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xeris Biopharma beats Zentalis Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Maravai LifeSciences?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Zentalis Pharmaceuticals has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Maravai LifeSciences has higher revenue and earnings than Zentalis Pharmaceuticals. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.29	-$137.06M	-$1.73	N/A
Maravai LifeSciences	$185.74M	6.12	-$130.77M	-$0.71	N/A

In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.64 beat Zentalis Pharmaceuticals' score of 0.49 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Zentalis Pharmaceuticals presently has a consensus price target of $5.83, suggesting a potential upside of 43.68%. Maravai LifeSciences has a consensus price target of $5.50, suggesting a potential upside of 25.00%. Given Zentalis Pharmaceuticals' higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Maravai LifeSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

50.3% of Maravai LifeSciences shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Maravai LifeSciences beats Zentalis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$289.02M	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.91	21.01	25.66
Price / Sales	4.29	329.35	615.84	111.99
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.58	7.09	10.37	7.14
Net Income	-$137.06M	$24.45M	$3.57B	$335.98M
7 Day Performance	11.85%	5.45%	6.01%	3.56%
1 Month Performance	2.01%	2.43%	3.52%	2.54%
1 Year Performance	238.33%	62.98%	34.13%	35.05%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	2.5806 of 5 stars	$4.06 flat	$5.83 +43.7%	+238.3%	$289.02M	$67.43M	N/A	160	Analyst Forecast
JBIO Jade Biosciences	2.0945 of 5 stars	$22.01 -5.7%	$34.33 +56.0%	N/A	$1.15B	N/A	N/A	20	Gap Up
AVLN Avalyn Pharma	N/A	$26.63 -10.8%	N/A	N/A	$1.11B	N/A	N/A	51	Analyst Forecast
COLL Collegium Pharmaceutical	2.9596 of 5 stars	$33.65 -0.4%	$57.50 +70.9%	+18.1%	$1.10B	$780.57M	16.50	210
XERS Xeris Biopharma	2.9898 of 5 stars	$6.01 -3.7%	$10.80 +79.7%	+28.2%	$1.08B	$291.85M	100.17	290	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. JBIO, AVLN, COLL, XERS, and MRVI

How does Zentalis Pharmaceuticals compare to Jade Biosciences?

Summary

How does Zentalis Pharmaceuticals compare to Avalyn Pharma?

Summary

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Summary

How does Zentalis Pharmaceuticals compare to Xeris Biopharma?

Summary

How does Zentalis Pharmaceuticals compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. JBIO, AVLN, COLL, XERS, and MRVI

How does Zentalis Pharmaceuticals compare to Jade Biosciences?

Is JBIO or ZNTL more profitable?

Does the media favor JBIO or ZNTL?

Which has better valuation and earnings, JBIO or ZNTL?

Which has more volatility & risk, JBIO or ZNTL?

Do analysts prefer JBIO or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Avalyn Pharma?

Do analysts prefer ZNTL or AVLN?

Is ZNTL or AVLN more profitable?

Does the media favor ZNTL or AVLN?

Which has stronger valuation & earnings, ZNTL or AVLN?

Summary

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Is COLL or ZNTL more profitable?

Does the media prefer COLL or ZNTL?

Which has preferable valuation and earnings, COLL or ZNTL?

Do analysts prefer COLL or ZNTL?

Which has more volatility and risk, COLL or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Xeris Biopharma?

Which has more volatility & risk, XERS or ZNTL?

Do institutionals & insiders have more ownership in XERS or ZNTL?

Which has stronger earnings & valuation, XERS or ZNTL?

Do analysts prefer XERS or ZNTL?

Is XERS or ZNTL more profitable?

Does the media favor XERS or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Maravai LifeSciences?

Which has more risk & volatility, ZNTL or MRVI?

Which has higher earnings & valuation, ZNTL or MRVI?

Does the media refer more to ZNTL or MRVI?

Is ZNTL or MRVI more profitable?

Do analysts recommend ZNTL or MRVI?

Do insiders & institutionals have more ownership in ZNTL or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools